Developer docs
API playgroundTry for free, no card

Search company profiles

DM Clinical Research

Full company profile

uuid0006ea4

Namestring
DM Clinical Research
Legal namestring
DM Clinical
Company typeenum
Private
Founded yearint
2006
Descriptiontext

DM Clinical Research is a private, Houston-based clinical research site network founded in 2005 that conducts Phase I-IV clinical trials across a multi-therapeutic portfolio spanning vaccines, internal medicine, pediatrics, gastroenterology, psychiatry, neurology, and women's health. The company operates 30+ dedicated and affiliate research sites across 15 U.S. states supported by 700+ employees, including 180+ dedicated patient recruiters, GCP-trained physicians, bilingual clinicians, and centralized budget, contracts, regulatory, and study start-up teams. Site-level technical capabilities include CLIA-certified laboratories, PBMC processing for vaccine and immunology trials, ultra-low temperature storage (-70C freezers with dry ice and 24-hour temperature monitoring), and IATA-certified staff for biological materials handling. The company maintains a 320K+ physician and research contact database and 28M total patient access to support rapid, diverse enrollment.

The business generates revenue through professional services contracts with pharmaceutical, biotechnology, and CRO customers, earning per-study fees tied to enrollment milestones, site activation, and trial completion. Vaccine trials (255+ completed) represent a meaningful specialty revenue stream. DM Clinical serves two primary customer segments: B2B sponsors and CROs seeking high-enrollment, demographically diverse site networks, and B2C patient volunteers recruited via a consumer-facing portal (dmclinicaltrials.com), bilingual phone line (281-517-0550), community outreach campaigns (e.g., #HoustonFightsCOVID), and an Ambassador referral program that compensates participants for successful referrals. Sponsors are engaged directly through a business development team and industry events such as the World Vaccine Congress.

The company is independently and privately held with no disclosed venture capital, private equity, or parent ownership in the available data; no funding rounds or M&A activity are documented. Leadership includes CEO Mohammad Millwala, and the firm has been recognized with multiple industry awards including Best Clinical Trial Network (World Vaccine Congress, 2023), SCRS Excellence in Patient Centricity (2022), and Best Clinical Trial Site (World Vaccine Congress, 2021).

Short descriptiontext

DM Clinical Research is a privately held, Houston-based clinical trial site network operating 30+ research sites across 15 U.S. states, conducting Phase I-IV multi-therapeutic trials for pharmaceutical, biotechnology, and CRO sponsors while recruiting patients directly through its consumer portal and bilingual outreach.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersHouston, United States
HQ citystring
Houston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices20 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical trial services, Phase I-IV trials, vaccine clinical research, patient recruitment services, multi-therapeutic site network
Industry1 code
PRIMARYHLAGACAE
Clinical Trial Site Operations & Study Coordination
NAICS code1 code
  • Research and Development in the Physical, Engineering, and Life Sciences54171
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Clinical Research Services
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1Clinical Trial Conduct Services for Sponsors/CROs
TypeProfessional Services
Description

DM Clinical earns fees from pharmaceutical and biotechnology companies for conducting Phase I-IV clinical trials at their site network. Revenue is generated per study contract based on enrollment milestones, site activation, and trial completion. The company also earns compensation per enrolled participant and for providing research infrastructure including facilities, staff, and regulatory support.

dmclinicalresearch.com
2Vaccine Trial Services
TypeProfessional Services
Description

Specialized revenue stream from conducting vaccine trials (255+ completed), including influenza, COVID-19, RSV, HPV, and other infectious disease vaccines. Vaccine trials represent a significant portion of the company's trial portfolio.

dmclinicalresearch.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure, Supply Chain
Pricing details1 tier
1Participant compensation for clinical trial participation
ModelOtherBilling cadencePay-as-you-go
Notes

Participants may receive compensation for study-related time and travel. Compensation amounts differ for each study. There is no cost to participate and participants may also receive study medicines or vaccines at no charge.

dmclinicalresearch.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

DM Clinical Research operates a network of 30+ dedicated and affiliate clinical trial investigator sites across the United States that conduct Phase I-IV clinical trials for pharmaceutical, biotechnology, and CRO sponsors across multiple therapeutic areas including vaccines, internal medicine, pediatrics, gastroenterology, psychiatry, neurology, and women's health. The company recruits patient participants through a consumer-facing portal and community outreach, and provides centralized budget, contracts, regulatory, and study start-up operations to support rapid trial activation and enrollment.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 1,000+ clinical trials conducted with 18,056+ participants enrolled
+3 more records
Product overview1 text field

DM Clinical Research is a multi-therapeutic clinical trial network that operates as a unified platform combining 30+ research sites across the United States. The core offering consists of Clinical Trial Network Services for conducting Phase I-IV studies, supported by a Patient Enrollment Platform (dmclinicaltrials.com) that connects patients with trials. Additional services include the Principal Investigator Partnership Program providing infrastructure access to physicians, and an Ambassador Referral Program for patient-driven recruitment. The company specializes in vaccines, internal medicine, pediatrics, gastroenterology, psychiatry, neurology, and women's health therapeutic areas.

Product and service1 record
1Clinical Trial Network Services
Scale indicator13 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Artisans of Medicine is a Brooklyn, NY-based medical practice that operates as a DM Clinical partnership site, performing a variety of clinical studies in the New York market.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Private, multi-therapeutic site network organization operating dedicated research sites across the U.S., directly comparable to DM Clinical in business model (SMO/site network), therapeutic breadth, and sponsor-facing services.

TypeBroad incumbent
Description

Largest global CRO with extensive site network, technology platforms, and data assets. Overlaps with DM Clinical on multi-therapeutic trial conduct and patient recruitment at scale, but at significantly greater scope and resources.

TypeBroad incumbent
Description

Global CRO formed through the PRA Health Sciences merger, with significant site-services and decentralized trial capabilities. A broad incumbent competing with DM Clinical for sponsor trial contracts across therapeutic areas.

TypeDirect peer
Description

Multi-site clinical research organization with therapeutic breadth and dedicated patient-recruitment capabilities, competing in the same mid-market U.S. site-network category as DM Clinical.

TypeBroad incumbent
Description

Large, publicly traded CRO with site-management and patient-recruitment offerings. Broader and more global than DM Clinical but serves overlapping sponsors and CRO-side customers with comparable site-network services.

TypeEmerging player
Description

Mid-sized, therapeutically focused CRO with site-management capabilities; partial overlap with DM Clinical in multi-therapeutic trial execution and sponsor-facing services, though more CRO-centric than pure site-network.

TypeBroad incumbent
Description

Mid-to-large CRO with embedded site operations and clinical trial management capabilities; broader portfolio than DM Clinical but overlaps in multi-therapeutic trial execution and sponsor-facing services.

TypeDirect peer
Description

Clinical research site network operating across the U.S. and Canada with integrated site operations, comparable to DM Clinical in offering Phase I-IV trials across multiple therapeutic areas to sponsors and CROs.

TypeDirect peer
Description

Multi-therapeutic clinical research site network conducting Phase I-IV trials for sponsors and CROs, with a similar diversified-therapeutics site-network model and patient-recruitment focus as DM Clinical.

TypeDirect peer
Description

Private, multi-site clinical research organization operating across multiple U.S. regions with Phase I-IV trial capabilities and vaccine/infectious disease expertise, comparable to DM Clinical's service offering.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

DM Clinical Research

Clinical Research Servicesdmclinicalresearch.com

DM Clinical Research is a privately held, Houston-based clinical trial site network operating 30+ research sites across 15 U.S. states, conducting Phase I-IV multi-therapeutic trials for pharmaceutical, biotechnology, and CRO sponsors while recruiting patients directly through its consumer portal and bilingual outreach.

What DM Clinical Research does

DM Clinical Research is a private, Houston-based clinical research site network founded in 2005 that conducts Phase I-IV clinical trials across a multi-therapeutic portfolio spanning vaccines, internal medicine, pediatrics, gastroenterology, psychiatry, neurology, and women's health. The company operates 30+ dedicated and affiliate research sites across 15 U.S. states supported by 700+ employees, including 180+ dedicated patient recruiters, GCP-trained physicians, bilingual clinicians, and centralized budget, contracts, regulatory, and study start-up teams. Site-level technical capabilities include CLIA-certified laboratories, PBMC processing for vaccine and immunology trials, ultra-low temperature storage (-70C freezers with dry ice and 24-hour temperature monitoring), and IATA-certified staff for biological materials handling. The company maintains a 320K+ physician and research contact database and 28M total patient access to support rapid, diverse enrollment.

The business generates revenue through professional services contracts with pharmaceutical, biotechnology, and CRO customers, earning per-study fees tied to enrollment milestones, site activation, and trial completion. Vaccine trials (255+ completed) represent a meaningful specialty revenue stream. DM Clinical serves two primary customer segments: B2B sponsors and CROs seeking high-enrollment, demographically diverse site networks, and B2C patient volunteers recruited via a consumer-facing portal (dmclinicaltrials.com), bilingual phone line (281-517-0550), community outreach campaigns (e.g., #HoustonFightsCOVID), and an Ambassador referral program that compensates participants for successful referrals. Sponsors are engaged directly through a business development team and industry events such as the World Vaccine Congress.

The company is independently and privately held with no disclosed venture capital, private equity, or parent ownership in the available data; no funding rounds or M&A activity are documented. Leadership includes CEO Mohammad Millwala, and the firm has been recognized with multiple industry awards including Best Clinical Trial Network (World Vaccine Congress, 2023), SCRS Excellence in Patient Centricity (2022), and Best Clinical Trial Site (World Vaccine Congress, 2021).

DM Clinical Research firmographics

Firmographics
Name
DM Clinical Research
Legal name
DM Clinical
Website
https://dmclinicalresearch.com
Company type
Private
Founded year
2006
Operating status
Operating
Headcount range
501–1,000 employees
Short description
DM Clinical Research is a privately held, Houston-based clinical trial site network operating 30+ research sites across 15 U.S. states, conducting Phase I-IV multi-therapeutic trials for pharmaceutical, biotechnology, and CRO sponsors while recruiting patients directly through its consumer portal and bilingual outreach.
Ownership category
akta.pro rank

DM Clinical Research industry classification

Industry
Product category
Clinical Research Services
NAICS
Research and Development in the Physical, Engineering, and Life Sciences (54171)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGACAE
Clinical Trial Site Operations & Study Coordination

Keywords

  • Clinical trial services
  • Phase I-IV trials
  • Vaccine clinical research
  • Patient recruitment services
  • Multi-therapeutic site network

Where DM Clinical Research is headquartered

Location

Headquarters

HQ city
Houston
HQ country
United States
HQ region
North America

Offices20 records

Markets served

DM Clinical Research business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure, Supply Chain

Revenue model

  1. Clinical Trial Conduct Services for Sponsors/CROs: DM Clinical earns fees from pharmaceutical and biotechnology companies for conducting Phase I-IV clinical trials at their site network. Revenue is generated per study contract based on enrollment milestones, site activation, and trial completion. The company also earns compensation per enrolled participant and for providing research infrastructure including facilities, staff, and regulatory support.
  2. Vaccine Trial Services: Specialized revenue stream from conducting vaccine trials (255+ completed), including influenza, COVID-19, RSV, HPV, and other infectious disease vaccines. Vaccine trials represent a significant portion of the company's trial portfolio.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goParticipant compensation for clinical trial participation

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

DM Clinical Research product offering

Product offering

Core offering

DM Clinical Research operates a network of 30+ dedicated and affiliate clinical trial investigator sites across the United States that conduct Phase I-IV clinical trials for pharmaceutical, biotechnology, and CRO sponsors across multiple therapeutic areas including vaccines, internal medicine, pediatrics, gastroenterology, psychiatry, neurology, and women's health. The company recruits patient participants through a consumer-facing portal and community outreach, and provides centralized budget, contracts, regulatory, and study start-up operations to support rapid trial activation and enrollment.

Product overview

DM Clinical Research is a multi-therapeutic clinical trial network that operates as a unified platform combining 30+ research sites across the United States. The core offering consists of Clinical Trial Network Services for conducting Phase I-IV studies, supported by a Patient Enrollment Platform (dmclinicaltrials.com) that connects patients with trials. Additional services include the Principal Investigator Partnership Program providing infrastructure access to physicians, and an Ambassador Referral Program for patient-driven recruitment. The company specializes in vaccines, internal medicine, pediatrics, gastroenterology, psychiatry, neurology, and women's health therapeutic areas.

Differentiator

Problem solved

Functional benefit

Products and services

  • Clinical Trial Network Services

Quantifiable outcome

  • 1,000+ clinical trials conducted with 18,056+ participants enrolled
  • +3 more outcomes

Companies that use DM Clinical Research

Customer profile

Named customers5 records

Segments4 records

Ideal customer profiles3 records

DM Clinical Research technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

DM Clinical Research partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Artisans of MedicineminorStrategic or Co-development PartnerArtisans of Medicine is a Brooklyn, NY-based medical practice that operates as a DM Clinical partnership site, performing a variety of clinical studies in the New York market.

Scale indicators13 records

Recent moves7 records

Expansion highlights5 records

DM Clinical Research competitors and assessment

Company assessment

Direct peers

  • Velocity Clinical Research: Private, multi-therapeutic site network organization operating dedicated research sites across the U.S., directly comparable to DM Clinical in business model (SMO/site network), therapeutic breadth, and sponsor-facing services.
  • Flourish Research: Multi-site clinical research organization with therapeutic breadth and dedicated patient-recruitment capabilities, competing in the same mid-market U.S. site-network category as DM Clinical.
  • Centricity Research: Clinical research site network operating across the U.S. and Canada with integrated site operations, comparable to DM Clinical in offering Phase I-IV trials across multiple therapeutic areas to sponsors and CROs.
  • Accel Research Sites: Multi-therapeutic clinical research site network conducting Phase I-IV trials for sponsors and CROs, with a similar diversified-therapeutics site-network model and patient-recruitment focus as DM Clinical.
  • Benchmark Research: Private, multi-site clinical research organization operating across multiple U.S. regions with Phase I-IV trial capabilities and vaccine/infectious disease expertise, comparable to DM Clinical's service offering.

Broad incumbents

  • IQVIA: Largest global CRO with extensive site network, technology platforms, and data assets. Overlaps with DM Clinical on multi-therapeutic trial conduct and patient recruitment at scale, but at significantly greater scope and resources.
  • ICON plc: Global CRO formed through the PRA Health Sciences merger, with significant site-services and decentralized trial capabilities. A broad incumbent competing with DM Clinical for sponsor trial contracts across therapeutic areas.
  • Syneos Health: Large, publicly traded CRO with site-management and patient-recruitment offerings. Broader and more global than DM Clinical but serves overlapping sponsors and CRO-side customers with comparable site-network services.
  • Medpace Holdings: Mid-to-large CRO with embedded site operations and clinical trial management capabilities; broader portfolio than DM Clinical but overlaps in multi-therapeutic trial execution and sponsor-facing services.

Emerging players

  • Clinipace Worldwide: Mid-sized, therapeutically focused CRO with site-management capabilities; partial overlap with DM Clinical in multi-therapeutic trial execution and sponsor-facing services, though more CRO-centric than pure site-network.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

DM Clinical Research social profiles

Digital presence

DM Clinical Research compliance and trust

Trust signal

Compliance3 records

DM Clinical Research financial estimates

Financial estimate

Revenue estimate

Valuation estimate

DM Clinical Research leadership team

Management profile

Number of profiles

Profiles1 record

DM Clinical Research funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

DM Clinical Research M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DM Clinical Research

What does DM Clinical Research do?

DM Clinical Research operates a network of 30+ dedicated and affiliate clinical trial investigator sites across the United States that conduct Phase I-IV clinical trials for pharmaceutical, biotechnology, and CRO sponsors across multiple therapeutic areas including vaccines, internal medicine, pediatrics, gastroenterology, psychiatry, neurology, and women's health. The company recruits patient participants through a consumer-facing portal and community outreach, and provides centralized budget, contracts, regulatory, and study start-up operations to support rapid trial activation and enrollment.

Is DM Clinical Research a public or private company?

DM Clinical Research is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was DM Clinical Research founded?

DM Clinical Research was founded in 2006. It employs 501 to 1,000 people.

Where is DM Clinical Research based?

DM Clinical Research is headquartered in Houston, United States, in the North America region.

How does DM Clinical Research make money?

Two revenue lines are on record. Clinical Trial Conduct Services for Sponsors/CROs are the primary driver. The others are vaccine Trial Services.

Who are DM Clinical Research's main competitors?

Direct peers on record are Velocity Clinical Research, Flourish Research, Centricity Research, Accel Research Sites and Benchmark Research. Broad incumbents are IQVIA, ICON plc, Syneos Health and Medpace Holdings. Clinipace Worldwide is listed as an emerging player.

Does DM Clinical Research have an API?

No public API is recorded for DM Clinical Research.

What industry is DM Clinical Research in?

DM Clinical Research's product category is Clinical Research Services. Its primary akta.pro industry code is HLAGACAE, Clinical Trial Site Operations & Study Coordination. Its NAICS code is 54171 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinancialContent Business PageDM Clinical Research Marks 20 Years of Advancing Clinical ResearchDM Clinical Research celebrated its 20th anniversary, marking two decades of expanding access to clinical trials and accelerating the development of innovative therapies in the United States. The organization now operates a network of over 35 research sites with access to a patient population of 1.97 million individuals across 32 therapeutic areas, having enrolled more than 35,000 patients historically. The company plans to continue its expansion into new communities and invest in innovative technologies to improve patient access during its third decade.24-7 Press ReleaseDM Clinical Research Marks 20 Years of Advancing Clinical ResearchDM Clinical Research celebrated its 20th anniversary, marking two decades of expanding patient access to clinical trials and accelerating the development of innovative therapies in the United States. The organization has grown into a network of over 35 research sites that have enrolled more than 35,000 patients across 32 therapeutic areas. Looking forward, the company plans to continue expanding into new communities and investing in technologies to improve patient access.PR NewswireDM Clinical Research Forms Inaugural Advisory Board to Accelerate Growth and InnovationDM Clinical Research announced its inaugural Advisory Board, comprising leaders from clinical research and healthcare, to provide strategic counsel on growth and innovation. The board includes Kushal Gohil, SVP at Parexel, and the company's CEO Mohammad Millwala said the board's expertise will help scale responsibly. The company, founded in 2006, operates over 35 research centers.ClearwatersecurityClinical Research Organizations: M&A Goldmine or Cyber Risk Liability?Private equity investment in Clinical Research Organizations (CROs) is accelerating due to market consolidation and technology innovation, creating significant M&A opportunities. However, this growth is accompanied by substantial cybersecurity risks, as illustrated by the exposure of 1.6 million patient records from DM Clinical Research, which highlights potential liabilities for investors. The article argues that integrating robust cybersecurity due diligence into M&A strategies is essential for protecting asset value and ensuring successful integration.GlobeNewswireIMUNON Announces Site Activation for IMNN-101 Phase 1 Vaccine StudyIMUNON announced that DM Clinical Research in Philadelphia is the first site activated for its Phase 1 study of IMNN-101, a seasonal COVID-19 vaccine using its PlaCCine platform. A second Boston site is expected to activate within weeks, with top-line data anticipated by year-end. The study will enroll 24 subjects evaluating three escalating doses.PR NewswireWes Bonner Joins DM Clinical Research as Vice President of Strategic RelationshipsWes Bonner, a clinical research industry veteran with over 25 years of experience, has joined DM Clinical Research as Vice President of Strategic Relationships. Bonner previously served in leadership roles at Meridian Clinical Research for 10 years, where he helped grow the site network from 3 to 36 sites and from 4 to 85 investigators. The company, headquartered in Houston and recognized by the World Vaccine Congress as the Best Clinical Trial Network, plans to leverage Bonner's physician relationships to expand its network with embedded practices in physician offices.PR NewswireDM Clinical Research Seeks Children & Adolescents for COVID-19, RSV, Lyme Disease and Migraine StudiesDM Clinical Research in Houston is seeking parents to enroll their children and adolescents in clinical studies for COVID-19, Lyme disease, migraine headaches, and RSV. The studies include investigational vaccines sponsored by Pfizer, Moderna, AbbVie, and Biohaven, aiming to provide access to treatments not yet available to the general public. Participating in these trials may offer benefits to the participants while advancing medical research.PR NewswireDM Clinical Research Opens New Research Site in Boston AreaDM Clinical Research, a national network of clinical trial sites headquartered in Houston, Texas, has opened its first research location in the Boston metropolitan area and Massachusetts, a 4,000-square-foot facility in Brookline. The company also announced a partnership with Moderna to enroll patients in the CMVictory Trial studying an investigational mRNA vaccine (mRNA-1647) for cytomegalovirus. DM Clinical reported rapid growth with 13 dedicated research centers and over 500 employees, and expects to continue its expansion trajectory toward becoming the leading independent clinical research network in the nation.AxiosResearchers bring push for clinical trial diversity to Boston areaDM Clinical Research opened a new Brookline site to boost diversity in clinical trials, its first Boston location with 15 employees. The company aims to recruit nearly a thousand Boston-area participants this year for studies on flu, RSV, and CMV. CEO Mohammad Millwala said the initiative addresses historical underrepresentation in research.PR NewswireDM Clinical Research Honored for Excellence in Patient CentricityDM Clinical Research, a national network of 12 clinical trial sites headquartered in Houston, Texas, has been awarded the Society for Clinical Research Sites (SCRS) 2022 Excellence in Patient Centricity Award, sponsored by Sanofi. The company was recognized for implementing patient-centric initiatives including streamlined communication channels, a Patient Advocates training program, and a patient survey system to track satisfaction metrics. The award was presented at the SCRS Eagle Award Gala during the SCRS Global Site Solutions Summit, with nominations cast by SCRS Global Impact Partners and member sites.